Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 841 to 855 of 1308 results for social care

  1. Workplace health: management practices (NG13)

    This guideline covers how to improve the health and wellbeing of employees, with a focus on organisational culture and the role of line managers.

  2. Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)

    Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Dravet syndrome in people aged 2 years and older.

  3. Gilteritinib for treating relapsed or refractory acute myeloid leukaemia (TA642)

    Evidence-based recommendations on gilteritinib (Xospata) for relapsed or refractory FLT3-mutation-positive acute myeloid leukaemia in adults.

  4. Digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people: early value assessment (HTG713)

    Early value assessment (EVA) guidance on digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people.

  5. The consequences and costs of poor transition:- What are the consequences and the costs of young people with ongoing needs not making a transition into adult services, or being poorly supported through the process?

    from children's to adults' services for young people using health or social care services Number NG43 Date issued February 2016

  6. Technology appraisal committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  7. Topotecan for the treatment of relapsed small-cell lung cancer (TA184)

    Evidence-based recommendations on topotecan for treating relapsed small-cell cancer in adults.

  8. Berotralstat for preventing recurrent attacks of hereditary angioedema (TA738)

    Evidence-based recommendations on berotralstat (Orladeyo) for preventing recurrent attacks of hereditary angioedema in people 12 years and older.

  9. Single technology appraisal and highly specialised technologies evaluation: User guide for company evidence submission template (PMG24)

    This is the user guide for submission of evidence to the National Institute for Health and Care Excellence (NICE) as part of the single technology appraisal and highly specialised technologies evaluations process. It explains what information NICE requires and the format in which it should be presented

  10. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  11. Neonatal infection: antibiotics for prevention and treatment (NG195)

    This guideline covers preventing bacterial infection in healthy babies of up to and including 28 days corrected gestational age, treating pregnant women and pregnant trans men and non-binary people whose unborn baby is at risk of infection, and caring for babies of up to and including 28 days corrected gestational age with a suspected or confirmed bacterial infection. It aims to reduce delays in recognising and treating infection and prevent unnecessary use of antibiotics. The guideline does not cover viral infections.

  12. Supporting young people to manage their conditions:- What is the relationship between transition and subsequent self-management?

    from children's to adults' services for young people using health or social care services Number NG43 Date issued February 2016

  13. One-piece closed bags for colostomies: late-stage assessment (HTG754)

    Late stage assessment (LSA) guidance on one-piece closed bags for colostomies

  14. Regorafenib for previously treated metastatic colorectal cancer (TA866)

    Evidence-based recommendations on regorafenib (Stivarga) for previously treated metastatic colorectal cancer in adults.

  15. Secukinumab for treating moderate to severe plaque psoriasis (TA350)

    Evidence-based recommendations on secukinumab (Cosentyx) for treating plaque psoriasis in adults.